Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled subcutaneous immunotherapy trial for grass and cupressaceae pollen allergy
2019-002865-37Phase 3Active
- Sponsor
- Inmunotek
- Start
- Nov 2020
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma comparing MG01-T521 active treatment with Placebo control (2 arms). Primary endpoint: Overall score of symptoms and medication throughout the trial. Started Nov 2020; status: active.
02
Drugs
MG01-T521
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2019-002865-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002865-37.